Mark Gilbert
NRG Oncology · Radiation Therapy Oncology Group · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark Gilbert as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:35 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT00884741 · Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed GlioblastomaNational Cancer Institute (NCI) · completed · Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma · principal investigator
- Ph2NCT00433381 · Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or GliosarcomaNational Cancer Institute (NCI) · completed · Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm · principal investigator
- Ph1/Ph2NCT00335764 · Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaNational Cancer Institute (NCI) · completed · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
- Ph2NCT00112866 · Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma MultiformeNational Cancer Institute (NCI) · terminated · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Bioinformatics: Characterizing Brain Tumor DataZIABC011784 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2017 to 2024 · $848,283 awarded in 2024Same name and institution; not confirmed by an ID
- Brain Tumor Clinical and Clinical Research ProgramZIDBC011642 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2015 to 2024 · $2,120,708 awarded in 2024Same name and institution; not confirmed by an ID
- CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors - CuresZIABC011853 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2020 to 2024 · $4,449,073 awarded in 2024Same name and institution; not confirmed by an ID
- Exploring the Therapeutic Potential of Stem Cell Biology in GliomasZIABC011640 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2015 to 2024 · $353,451 awarded in 2024Same name and institution; not confirmed by an ID
- Identifying New Glioma-Associated Tumor Suppressors and OncogenesZIABC011647 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2015 to 2024 · $494,832 awarded in 2024Same name and institution; not confirmed by an ID
- Pre-clinical Translational Research FacilityZICBC011641 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2015 to 2024 · $2,262,089 awarded in 2024Same name and institution; not confirmed by an ID
- Rare Central Nervous System Cancers InitiativeZIABC011643 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2015 to 2024 · $494,832 awarded in 2024Same name and institution; not confirmed by an ID
- Translational ImmunologyZIABC011714 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2016 to 2024 · $494,832 awarded in 2024Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT00884741
- Radiation Therapy Oncology GroupU10CA021661 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI Walter J. Curran · fiscal years 1985 to 2013Named on NCT00884741, NCT00433381
- Adult Brain Tumor Consortium (ABTC)U01CA137443 · NCI · JOHNS HOPKINS UNIVERSITY · PI STUART A GROSSMAN, MICHAEL D PRADOS · fiscal years 2009 to 2013Named on NCT00335764
- NABTC Central Operation Grant (UCSF Project Leader)U01CA062399 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MICHAEL D PRADOS · fiscal years 1994 to 2008Named on NCT00112866
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 08:35 UTC. The ranking covers the 200 most relevant of 60 PubMed records, and a shared surname and initials can bring in a namesake. All 60 on PubMed
- A randomized trial of bevacizumab for newly diagnosed glioblastoma.N Engl J Med · 20142,246 citationsRCR 69.8
- Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.J Clin Oncol · 2013843 citationsRCR 26.0
- 650 citationsRCR 14.4
- Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.Clin Cancer Res · 2006319 citationsRCR 7.0
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.Neuro Oncol · 2011295 citationsRCR 6.9
- A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.Neuro Oncol · 2010220 citationsRCR 5.3
- Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.J Clin Oncol · 2011175 citationsRCR 4.5
- Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.J Clin Oncol · 2019146 citationsRCR 5.1
- Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.Neuro Oncol · 2023143 citationsRCR 13.8
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.Neuro Oncol · 2014139 citationsRCR 4.0